Product Information
PHENTERMINE 37.5 MG TABLET is a generic product labeled by TAGI Pharma Inc., priced at $0.0697 per EA under NDC 51224010150. Its NADAC has been published 639 times since Nov 28, 2013.
FDA first approved this application on Jan 31, 2011. Its Orange Book therapeutic-equivalence code is AA.
Strength
37.5 mg/1
Manufacturer
TAGI Pharma Inc.NDC
51224010150
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA200272FDA Approved
1/31/2011
TE Code
AA
On Market Since
3/8/2011
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE 37.5 MG TABLET has been published 639 times since Nov 28, 2013, and over the history we have for it it has declined 34.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0697 per EA |
|---|---|
| All-time high | $0.1304 (Apr 16, 2014) |
| All-time low | $0.0494 (Nov 20, 2024) |
| 52-week high | $0.0708 |
| 52-week low | $0.0670 |
| Median price | $0.0905 |
| Average price | $0.0926 |
| Largest weekly change | +51.9% (Jun 19, 2024) |
| Weeks tracked | 639 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-1.6%
3Y
-6.9%
5Y
-16.0%
All
-34.1%
Last surveyed Feb 18, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
TAGI Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Phentermine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE 37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE 37.5 MG TABLET, manufactured by TAGI Pharma Inc., is $0.0697 per EA (NDC 51224010150), effective Feb 18, 2026.
How has the price of PHENTERMINE 37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for PHENTERMINE 37.5 MG TABLET has declined 34.1%. It has been tracked across 639 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PHENTERMINE 37.5 MG TABLET?
Since Nov 28, 2013, the NADAC for PHENTERMINE 37.5 MG TABLET has ranged from a low of $0.0494 (Nov 20, 2024) to a high of $0.1304 (Apr 16, 2014), with a median of $0.0905 per EA.
Are there cheaper alternatives to PHENTERMINE 37.5 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PHENTERMINE 37.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PHENTERMINE 37.5 MG TABLET?
PHENTERMINE 37.5 MG TABLET (NDC 51224010150) is labeled by TAGI Pharma Inc., and CMS classifies it as a generic product.